Möchten Sie immer auf dem neuesten Stand bleiben?

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Curium’s strategic investment of over €32 million will establish a European production line for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate...

EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June...

NUCLIDIUM announced a CHF 26.4 million extension led by existing investors to accelerate clinical development of NU101 and NU201 radiotheranostic programs.

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence

, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026 AUSTIN,...

WASHINGTON, DC, May 15, 2026 (GLOBE NEWSWIRE) -- From the foods men eat to how surgery is planned and public awareness unfolds, new research presented at the American Urological Association (AUA)...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of EpCAM-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Her3-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...